Recent anticancer agents targeting sphingolipid pathways

Bibliography

• FAHEY E, SUBRAMANIAM S, BROWN HA et al.: A comprehensive classification system for lipids. J. Lipid Res. (2005) 46(5):839-861.
   PubMedGoogle Scholar
• NICKOLOVA-KARAKASHIAN M: Sphingolipid-mediated signal transduction. In: Molecular Biology Intelligence Unit. YA Hannun (Ed.), RG Landes Co. (1997):159.
   Google Scholar
• HAKOMORI S: New directions in cancer therapy based on aberrant expression of glycosphingolipids; antiadhesion and ortho-signaling therapy. Cancer Cell (1991) 3:461-470.
   PubMed Web of Science ®Google Scholar
• HAKOMORI S: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. (1996) 56:5309-5318.
   PubMed Web of Science ®Google Scholar
• MARTINOVA EA: Influence of sphingolipids on T lymphocyte activation. Biochemistry (Moscow) (1998) 63(1):102-122.
   PubMedGoogle Scholar
• FUTERMAN A: Distinct roles for sphingolipids and glycosphingolipids at different stages of neuronal development. Acta Biochim. Pol. (1998) 45(2):469-478.
   PubMedGoogle Scholar
• KARIYA Y, KIHARA A, IKEDA M et al.: Products by the sphingosine kinase/sphingosine 1-phosphate (S1P) lyase pathway but not S1P stimulate mitogenesis. Genes Cells (2005) 10(6):605-615.
   PubMed Web of Science ®Google Scholar
• LAMOUR NF, CHALFANT CE: Ceramide-1-phosphate: the ‘missing’ link in eicosanoid biosynthesis and inflammation. Mol. Interv. (2005) 5(6):358-367.
   PubMedGoogle Scholar
• MACEYKA M, SANKALA H, HAIT NC et al.: SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem. (2005) 280(44):37118-37129.
   PubMed Web of Science ®Google Scholar
• STEVENS VL, WINTON EF, SMITH EE, OWENS NE, KINKADE JM Jr, MERRILL AH Jr: Differential effects of long-chain (sphingoid) bases on the monocytic differentiation of human leukemia (HL-60) cells induced by phorbol esters, 1α, 25-dihydroxyvitamin D3, or ganglioside GM3. Cancer Res. (1989) 49(12):3229-3234.
   PubMedGoogle Scholar
• BOREK C, ONG A, STEVENS VL, WANG E, MERRILL AH Jr: Long-chain (sphingoid) bases inhibit multistage carcinogenesis in mouse C3H/10T1/2 cells treated with radiation and phorbol 12-myristate 13-acetate. Proc. Natl. Acad. Sci. USA (1991) 88(5):1953-1957.
   PubMedGoogle Scholar
• STEVENS VL, NIMKAR S, JAMISON WC, LIOTTA DC, MERRILL AH Jr: Characteristics of the growth inhibition and cytotoxicity of long-chain (sphingoid) bases for Chinese hamster ovary cells: evidence for an involvement of protein kinase C. Biochim. Biophys. Acta. (1990) 1051(1):37-45.
   PubMedGoogle Scholar
• ENKVETCHAKUL B, MERRILL AH Jr, BIRT DF: Inhibition of ornithine decarboxylase activity in mouse epidermis by sphingosine sulfate. Carcinogenesis (1989) 10:379-381.
   PubMedGoogle Scholar
• ENKVETCHAKUL B, BARNETT T, LIOTTA DC et al.: Influences of sphingosine on two-stage skin tumorigenesis in SENCAR mice. Cancer Lett. (1992) 62:35-42.
   PubMedGoogle Scholar
• DILLEHAY DL, WEBB SK, SCHMELZ E-M, MERRILL AH Jr: Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J. Nutr. (1994) 124:615-620.
   PubMed Web of Science ®Google Scholar
• SCHMELZ EM, DILLEHAY D, WEBB S, REITER A, ADAMS J, MERRILL AH Jr: Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res. (1996) 56:4936-4941.
   PubMed Web of Science ®Google Scholar
• SCHMELZ EM, ROBERTS, PC, KUSTIN EM et al.: Modulation of intracellular β-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res. (2001) 61:6723-6729.
   PubMed Web of Science ®Google Scholar
• VESPER H, SCHMELZ E-M, NIKOLOVA-KARAKASHIAN MN, DILLEHAY DL, LYNCH DV, MERRILL AH Jr: Sphingolipids in food and the emerging importance of sphingolipids in nutrition. J. Nutr. (1999) 129:1239-1250.
   PubMed Web of Science ®Google Scholar
• SCHMELZ E-M, CRALL KJ, LAROCQUE R, DILLEHAY DL, MERRILL AH Jr: Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J. Nutr. (1994) 124:702-712.
   PubMed Web of Science ®Google Scholar
• IMAIZUMI K, TOMINAGA A, SATO M, SUGANO M: Effects of dietary sphingolipids on levels of serum and liver lipids in rats. Nutr. Res. (1992) 12:543-548.
   Web of Science ®Google Scholar
• MIZUTANI Y, KIHARA A, IGARASHI Y: Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem. J. (2005) 390(Pt 1):263-271.
   PubMed Web of Science ®Google Scholar
• KOYBASI S, SENKAL CE, SUNDARARAJ K et al.: Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J. Biol. Chem. (2004) 279(43):44311-44319.
   PubMed Web of Science ®Google Scholar
• MERRILL AH Jr, WANG E, GILCHRIST DG, RILEY RT: Fumonisins and other inhibitors of de novo sphingolipid biosynthesis. Adv. Lipid Res. (1993) 26:215-234.
   PubMedGoogle Scholar
• MICHEL C, VAN-ECHTEN-DECKERT G, ROTHER J, SANDHOFF K, WANG E, MERRILL AH Jr: Characterization of ceramide synthesis; a dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide. J. Biol. Chem. (1997) 272:22432-22437.
   PubMed Web of Science ®Google Scholar
• TRINCHERA M, GHIDONI R, SONNINO S, TETTAMANTI G: Recycling of glucosylceramide and sphingosine for the biosynthesis of gangliosides and sphingomyelin in rat liver. Biochem. J. (1990) 270(3):815-820.
   PubMedGoogle Scholar
• HANADA K: New paradigm of membrane transport: ER-to-golgi trafficking of the lipid ceramide by a molecular extraction and transfer mechanism. Nippon Saikingaku Zasshi. (2005) 60(4):531-537.
   PubMedGoogle Scholar
• DOLGACHEV V, FAROOQUI MS, KULAEVA OI et al.: De novo ceramide accumulation due to inhibition of its conversion to complex sphingolipids in apoptotic photosensitized cells. J. Biol. Chem. (2004) 279(22):23238-23249.
   PubMedGoogle Scholar
• SWEENEY EA, IGARASHI Y: Increases in ceramide levels in normal human mesangial cells subjected to different cellular stresses result from changes in distinct enzyme activities and can influence cellular responses to other stimuli. J. Biochem. (Tokyo) (1999) 125(4):737-745.
   PubMedGoogle Scholar
• LIU H, TOMAN RE, GOPARAJU SK et al.: Sphingosine kinase Type 2 is a putative BH3-only protein that induces apoptosis. J. Biol. Chem. (2003) 278(41):40330-40336.
   PubMed Web of Science ®Google Scholar
• REISS U, OSKOUIAN B, ZHOU J et al.: Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. J. Biol. Chem. (2004) 279(2):1281-1290.
   PubMed Web of Science ®Google Scholar
• MERRILL AH Jr, SCHMELZ EM, DILLEHAY DL et al.: Sphingolipids – the enigmatic lipid class; biochemistry, physiology, and pathophysiology. Toxicol. Appl. Pharmcol. (1997) 142:208-225.
   PubMed Web of Science ®Google Scholar
• OGRETMEN B, HANNUN YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer (2004) 4(8):604-616.
   PubMed Web of Science ®Google Scholar
• LIU Y-Y, HAN T-Y, GIULIANO AE, HANSEN N, CABOT MC: Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem. (2000) 275:7138-7143.
   PubMed Web of Science ®Google Scholar
• BIELAWSKA A, LINARDIC CM, HANNUN YA: Modulation of cell growth and differentiation by ceramide. FEBS Lett. (1992) 307:211-214.
   PubMedGoogle Scholar
• FREDMAN P, WIKSTRAND CJ, MANSSON JE et al.: In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54 MG cell line. Glycoconj. J. (1996) 13:391-399.
   PubMedGoogle Scholar
• HANDA K, KOJIMA N, HAKOMORI S: Analysis of glycolipid-dependent cell adhesion based on carbohydrate–carbohydrate interaction. Meth. Enzymol. (2000) 312:447-458.
   PubMedGoogle Scholar
• MERZAK A, KOOCHEKPOUR S, MCCREA S, ROXANIS Y, PILKINGTON GJ: Gangliosides modulate proliferation, migration, and invasiveness of human brain tumor cells in vitro. Mol. Chem. Neuropathol. (1995) 24:121-135.
   PubMedGoogle Scholar
• LI R, MANELA J, KONG Y, LADISCH S: Cellular gangliosides promote growth factor-induced proliferation of fibroblasts. J. Biol. Chem. (2000) 275:34213-34223.
   PubMedGoogle Scholar
• ZICHE M, MORBIDELLI L, ALESSANDRI G, GULLINO PM: Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio. Lab. Invest. (1992) 67:711-715.
   PubMed Web of Science ®Google Scholar
• MCKALLIP R, LI R, LADISCH S: Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol. (1999) 163:3718-3726.
   PubMed Web of Science ®Google Scholar
• INOKUCHI J-I, MASON I, RADIN NS: Antitumor activity in mice of an inhibitor of glycosphingolipid biosynthesis. Cancer Lett. (1987) 38:23-30.
   PubMed Web of Science ®Google Scholar
• INOKUCHI J, JIMBO M, MOMOSAKI K, SHIMENO H, NAGAMATSU A, RADIN NS: Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action. Cancer Res. (1990) 50:6731-6737.
   PubMed Web of Science ®Google Scholar
• RADIN NS SHAYMAN JA: Use of an inhibitor of glucosylceramide synthase, 1-phenyl-2-decanoylamino-3-morpholino-propanol (PDMP), an inhibitor of glucosylceramide synthesis. In: NeuroProtocols, A Companion to Methods in Neurosciences. SK Fisher et al. (Eds), Academic Press, San Diego, USA (1993) 3:145-155.
   Google Scholar
• RADIN NS SHAMAN JA, INOKUCHI J: Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. In: Advances in Lipid Research; Sphingolipids in Signaling, Part B. RM Bell et al. (Eds), Academic Press, San Diego, USA (1993) 28:183-213.
   Google Scholar
• JACOB GS, SCUDDER P: Glycosidases in structural analysis. Meth. Enzymol. (1994) 230:280-299.
   PubMedGoogle Scholar
• PLATT FM, NEISES GR, KARLSSON GB, DWEK RA, BUTTERS TD: N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J. Biol. Chem. (1994) 269:27108-27114.
   PubMed Web of Science ®Google Scholar
• LUCCI A, CHO WI, HAN T-Y, GIULIANO AE, MORTON DL, CABOT MC: Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res. (1998) 18(1B):475-480.
   PubMed Web of Science ®Google Scholar
• LAVIE Y, CAO HT, VOLNER A et al.: Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem. (1997) 272:1682-1687.
   PubMed Web of Science ®Google Scholar
• NICHOLSON KM, QUINN DM, KELLETT GL, WARR JR: Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br. J. Cancer (1999) 81:423-430.
   PubMedGoogle Scholar
• LIU Y-Y, HAN T-Y, GIULIANO AE, CABOT MC: Expression of glucosylceramide synthase, converting ceramide to glucosylceramide confers adriamycin resistance in human breast cancer cells. J. Biol. Chem. (1999) 274:1140-1146.
   PubMed Web of Science ®Google Scholar
• LINARDIC CM, HANNUN YA: Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle. J. Biol. Chem. (1994) 269:23530-23537.
   PubMed Web of Science ®Google Scholar
• LIU B, OBIED LM, HANNUN YA: Sphingomyelinases in cell regulation. Semin. Cell. Dev. Biol. (1997) 8:311-322.
   PubMedGoogle Scholar
• WIEDER T, ORFANOS CE, GEILEN CC: Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J. Biol. Chem. (1998) 273:11025-11031.
   PubMedGoogle Scholar
• KOIZUMIA K, SHIMIZUB S, KOIZUMIA KT et al.: Rapid isolation and lipid characterization of plasma membranes from normal and malignant lymphoid cells of mouse. Biochim. Biophys. Acta (1991) 649:393-403.
   Google Scholar
• VAN BLITTERSWIJK WJ, HILKMANN H, HENGEVELD T: Differences in membrane lipid composition and fluidity of transplanted grsl lymphoma cells, depending on their site of growth in the mouse. Biochim. Biophys. Acta (1984) 778:521-529.
   PubMedGoogle Scholar
• SPIEGEL S, MILSTIEN S: Sphingosine 1-phosphate: an enigmatic signaling lipid. Nat. Rev. Mol. Cell Biol. (2003) 5:397-407.
   Google Scholar
• SADAHIRA Y, RUAN F, HAKOMORI S, IGARASHI Y: Sphingosine 1-phosphate, a specific endogeneous signaling molecule controlling cell motility and tumor cell invasiveness. Proc. Natl. Acad. Sci USA (1992) 89:9686-9690.
   PubMedGoogle Scholar
• LEE MJ, THANGADA S, CLAFFEY KP et al.: Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine 1-phosphate. Cell (1999) 99:301-312.
   PubMed Web of Science ®Google Scholar
• HISANO N, YATOMI Y, SATOH K et al.: Induction and suppression of endothelial cell apoptosis by sphingolipids: a possible in vitro model for cell–cell interactions between platelets and endothelial cells. Blood (1999) 93:4293-4299.
   PubMed Web of Science ®Google Scholar
• XIA P, WANG L, BAMBLE JR, VADAS MA: Activation of sphingosine kinase by tumor necrosis factor inhibits apoptosis in human endothelial cells. J. Biol. Chem. (1999) 274:34499-34505.
   PubMed Web of Science ®Google Scholar
• MILSTIEN S, SPIEGEL S: Targeting sphingosine 1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell (2006) 3:148-150.
   Google Scholar
• LAMONTAGNE K, LITTLEWOOD-EVANS A, SCHNELL C et al.: Antagonism of sphingosine 1-phosphate receptors by FTY-720 inhibits angiogenesis and tumor vascularization. Cancer Res. (2006) 66:221-231.
   PubMed Web of Science ®Google Scholar
• HO JW, MAN K, SUN CK, LEE TK, POON RTP, FAN ST: Effects of a novel immunomodulating agent, FTY-720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol. Cancer Ther. (2005) 4:1430-1438.
   PubMedGoogle Scholar
• CHUA CW, LEE DT, LING MT et al.: FTY-720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int. J. Cancer (2005) 117:1039-1048.
   PubMed Web of Science ®Google Scholar
• VISENTIN B, VEKICH JA, SIBBALD BJ et al.: Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell (2006) 9:225-238.
   PubMed Web of Science ®Google Scholar
• XIA P, VADAS MA, RYE K, BARTER PJ, GAMBLE JR: High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway: a possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. (1999) 274:33143-33147.
   PubMed Web of Science ®Google Scholar
• LEE MJ, VAN BROCKLYN JR, THANGADA S et al.: Sphingosine-1-phosphate as a ligand for the G-protein coupled receptor EDG-1. Science (1998) 279:1552-1555.
   PubMed Web of Science ®Google Scholar
• ANCELLIN N, HLA T: Differential pharmacological properties and signal transduction of the sphingosine-1-phosphate receptors EDG-1, -3, and -5. J. Biol. Chem. (1999) 274:18997-19002.
   PubMed Web of Science ®Google Scholar
• LINN SC, KIM HS, KEANE EM, ANDRAS LM, WANG E, MERRILL AH Jr: Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. Biochem. Soc. Trans. (2001) 29(Pt 6):831-835.
   PubMed Web of Science ®Google Scholar
• BUEHRER BM, BELL RM: Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways. J. Biol. Chem. (1992) 267:3154-3159.
   PubMed Web of Science ®Google Scholar
• HUMPF H-U, SCHMELZ E-M, MEREDITH FI et al.: Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase: formation of N-palmitoyl-aminopentol (PAP1) produces a toxic metabolite of hydrolyzed fumonisin (AP1), and a new category of ceramide synthase inhibitor. J. Biol. Chem. (1998) 273:19060-19066.
   PubMed Web of Science ®Google Scholar
• DRAGUSIN M, GURGUI C, SCHWARZMANN G, HOERNSCHEMEYER J, VAN ECHTEN-DECKERT G: Metabolism of the unnatural anticancer lipid safingol, l-threo-dihydrosphingosine, in cultured cells. J. Lipid Res. (2003) 44:1772-1779.
   PubMedGoogle Scholar
• KEDDERIS LB, BOZIGIAN HP, KLEEMAN JM et al.: Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam. Appl. Toxicol. (1995) 25:201-217.
   PubMedGoogle Scholar
• SCHWARTZ GK, WARD D, SALTZ L et al.: A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin. Cancer Res. (1997) 3(4):537-543.
   PubMed Web of Science ®Google Scholar
• SMITH ER, JONES PL, BOSS JM, MERRILL AH Jr: Changing J774A.1 cells to new medium perturbs multiple signaling pathways, including the modulation of protein kinase C by endogenous sphingoid bases. J. Biol. Chem. (1997) 272:5640-5646.
   PubMedGoogle Scholar
• MEREDITH JE Jr, FAZELI B, SCHWARTZ MA: The extracellular matrix as a cell survival factor. Mol. Biol. Cell. (1993) 4:953-961.
   PubMed Web of Science ®Google Scholar
• RE F, ZANETTI A, SIRONI M et al.: Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J. Cell Biol. (1994) 127:537-546.
   PubMed Web of Science ®Google Scholar
• FREIDLANDER M, BROOKS PC, SHAFFER RW, KINCAID CM, VARNER JA, CHERESH DA: Definition of two angiogenic pathways by distinct integrins. Science (1995) 270:1500-1502.
   PubMedGoogle Scholar
• BIERCERICH E, SILVA J, WANG G, KRISHNAMURTHY K, CONDI BG: Selective apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues prevents teratoma formation and enriches for neural precursors in ES cells-derived neural transplants. J. Cell Biol. (2004) 4:723-734.
   Google Scholar